Skip to main content
. Author manuscript; available in PMC: 2022 Feb 17.
Published in final edited form as: Cell Rep. 2021 Jun 29;35(13):109301. doi: 10.1016/j.celrep.2021.109301

Figure 2. Acute hepatic GABA-transaminase knockdown improves obesity-induced metabolic dysfunction.

Figure 2.

(A) GABA-T mRNA expression in liver, whole brain, and pancreas after 1 week of injections with a GABA-T targeted or scramble control antisense oligonucleotide (ASO) (12.5 mg/kg i.p. twice weekly) in high-fat-diet-induced obese mice.

(B) Release of GABA (μmol/mg DNA) from hepatic slices.

(C) Body weight during treatment.

(D–F) Basal serum insulin (D), glucose (E), and glucose:insulin ratio (F).

(G–K) OGTT (G), OGTT AUC (H), oral glucose-stimulated serum insulin (I), ITT (J), and ITT AUC (K).

Number below bar denotes n per group. All data are presented as mean ± SEM.